+ Follow MEDICINAL PRODUCTS Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 731565
[Title] => Treatment for advanced ovarian cancer receives positive opinion
[Summary] => BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 568687
[Title] => Roche's lung cancer drug receives positive opinion in Europe
[Summary] => Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
[DatePublished] => 2010-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] => 1475655
[AuthorName] => LPM
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[2] => Array
(
[ArticleID] => 302759
[Title] => Exubera gets positive opinion from EMEA
[Summary] => PARIS Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
MEDICINAL PRODUCTS
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 731565
[Title] => Treatment for advanced ovarian cancer receives positive opinion
[Summary] => BASEL, Switzerland — Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of bevacizumab in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line treatment for women with advanced ovarian cancer.
[DatePublished] => 2011-09-29 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 568687
[Title] => Roche's lung cancer drug receives positive opinion in Europe
[Summary] => Roche recently announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of erlotinib as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy.
[DatePublished] => 2010-04-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] => 1475655
[AuthorName] => LPM
[SectionName] => Cebu News
[SectionUrl] => cebu-news
[URL] =>
)
[2] => Array
(
[ArticleID] => 302759
[Title] => Exubera gets positive opinion from EMEA
[Summary] => PARIS Sanofi-aventis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of Exubera (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes.
[DatePublished] => 2005-10-20 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
September 29, 2011 - 12:00am
By
LPM | April 23, 2010 - 12:00am
October 20, 2005 - 12:00am